Exelixis, Inc.
210 East Grand Avenue
South San Francisco
California
94083-0511
U.S.A.
Phone:
650-837-7000
Fax:
650-837-8300
|
Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo.
By investing in robust discovery and preclinical development infrastructure, the company has been able to bring very high quality compounds into the clinic in rapid fashion. Just four years after filing its first investigational new drug application (IND) to begin clinical trials of a proprietary compound, Exelixis has 14 compounds in clinical development and is positioned to build a leading franchise in cancer therapeutics.
A fundamental philosophy at Exelixis is the belief that advancing the treatment of cancer necessitates increased understanding of the disease itself. A key component of the company’s strategy is to gain insight into the complex molecular mechanisms that drive the growth, survival, and resistance of cancer cells, and utilize this knowledge to simplify, streamline, and inform the entire drug development process. This approach allows Exelixis to be both innovative and strategic while moving quickly in the right direction.
Recognizing that diverse molecular pathways impact the development, progression, spread, and survival of different cancer types, Exelixis is building a pipeline of compounds with unique target profiles. This approach allows the development of individual drug candidates for those cancer indications and patient populations where the pharmacology of the compound addresses the biology of the disease.
Exelixis’ ability to take this approach is a result of the company’s extensive expertise in pathway biology, and is supported by an integrated approach to discovery, translational medicine, and clinical development. Everyone at Exelixis believes that extensive discovery research isn’t just good science – it is also critical to good medicine. By understanding target biology and compound activity early on, Exelixis researchers seek to identify those patients most likely to benefit from a given drug candidate, and pursue a clearly defined path through the clinic and toward the market.
To support its robust and growing product pipeline, Exelixis is establishing a seamlessly integrated R&D organization with the critical mass to leverage data effectively and the flexibility to incorporate new insights into our strategies. The ability to make rational and data-driven decisions at each point along the drug development continuum strengthens the entire process. Extensive target characterization enhances the company’s ability to select indications and patient populations in which its drug candidates are most likely to provide benefit, and its experiences in the clinic help to identify additional areas of unmet medical need on which future discovery and development efforts can be focused.
Email:
info@exelixis.com
Ownership:
Web Site:
Exelixis, Inc.
Employees:
450
Symbol: EXEL
|
|
|
Company News |
Exelixis, Inc. (EXEL) Reports Encouraging Phase 1 Data for the PI3K Inhibitor Xl147 (SAR245408) in Combination with Erlotinib at the AACR-NCI-EORTC Conference
11/18/2009 11:00:47 AM
More...
|
Exelixis, Inc. (EXEL) Reports Encouraging Phase 1 Data for the PI3K Inhibitor XL147 (SAR245408) in Combination with Paclitaxel and Carboplatin at the AACR-NCI-EORTC Conference
11/17/2009 11:32:25 AM
More...
|
Exelixis, Inc. (EXEL) Announces November 18 Webcast of Presentation at Lazard's 6th Annual Healthcare Conference
11/13/2009 9:06:02 AM
More...
|
Thirteen Abstracts Featuring Exelixis, Inc. (EXEL) Compounds Accepted for Presentation at the 2009 American Association for Cancer Research-National Cancer Institute-EORTC International Conference
11/4/2009 9:33:55 AM
More...
|
Ligand Pharmaceuticals Inc. (LGND) Updates License Agreement with Exelixis, Inc. (EXEL)
11/2/2009 9:41:55 AM
More...
|
Exelixis, Inc. (EXEL) Announces Third Quarter 2009 Financial Results
10/30/2009 9:20:44 AM
More...
|
Exelixis, Inc. (EXEL) and Bristol-Myers Squibb Company (BMY) Report New Phase 2 Data for XL184 in Patients With the Most Common and Aggressive Form of Brain Cancer
10/26/2009 9:50:31 AM
More...
|
Exelixis, Inc. (EXEL) Announces October 29 Webcast of Third Quarter 2009 Financial Results Conference Call
10/14/2009 9:50:00 AM
More...
|
Exelixis, Inc. (EXEL) Announces Webcasts of Three Presentations at Healthcare and Biotechnology Conferences in September 2009
9/4/2009 9:05:38 AM
More...
|
Exelixis, Inc. (EXEL) Announces August 11 Webcast of Presentation at the Canaccord Adams 29th Annual Global Growth Conference
8/10/2009 10:02:54 AM
More...
|
|
|
|